# TP53

## Overview
The TP53 gene is a critical component of the human genome, encoding the tumor suppressor protein p53, which plays a pivotal role in maintaining cellular integrity and preventing tumorigenesis. As a transcription factor, p53 is involved in regulating the expression of genes that control cell cycle arrest, DNA repair, and apoptosis in response to cellular stressors such as DNA damage and oncogene activation (Aubrey2016Tumor-Suppressor; Hafner2019The). The protein is characterized by its ability to form a homotetramer, which is essential for its DNA-binding function, and is subject to various post-translational modifications that modulate its activity (Joerger2010The; Uversky2016p53). Mutations in the TP53 gene are among the most common genetic alterations in human cancers, often leading to the loss of its tumor suppressive functions and contributing to cancer progression (Chen2022Mutant; Olivier2009TP53). The study of TP53 and its encoded protein p53 continues to be a significant focus in cancer research, with implications for understanding cancer pathogenesis and developing targeted therapies (Engin2016StructureBased).

## Structure
The TP53 gene encodes the tumor suppressor protein p53, which consists of 393 amino acids and is organized into several functional domains. The primary structure includes an amino-terminal transactivation domain (TAD), a central DNA-binding domain (DBD), a tetramerization domain (TD), and a carboxy-terminal regulatory domain (CTD) (Uversky2016p53; Römer2006p53—A). The secondary structure of p53 features alpha helices and beta sheets, with the DBD containing a central immunoglobulin-like beta-sandwich scaffold (Joerger2010The).

The tertiary structure of p53 is highly dynamic, allowing it to interact with numerous partner proteins. It forms a tetramer, which is essential for its DNA-binding function (Joerger2010The; Uversky2016p53). The tetramerization domain is stabilized by an antiparallel intermolecular beta-sheet and helix-packing interactions (Joerger2010The).

Post-translational modifications, such as phosphorylation, acetylation, ubiquitination, and methylation, play crucial roles in regulating p53's activity and stability (Uversky2016p53). The TP53 gene also produces multiple isoforms through alternative splicing, which can affect the protein's function and interactions (Uversky2016p53). These structural features and modifications enable p53 to act as a versatile molecular sensor in cellular processes.

## Function
The TP53 gene encodes the p53 protein, a critical transcription factor involved in maintaining genomic stability in healthy human cells. p53 is activated in response to various cellular stresses, such as DNA damage, hypoxia, and oncogene activation, and functions primarily as a transcriptional activator. It induces the expression of target genes that regulate cell cycle arrest, DNA repair, and apoptosis, thereby preventing the propagation of damaged DNA (Aubrey2016Tumor-Suppressor; Hafner2019The).

In its role as a tumor suppressor, p53 is involved in multiple cellular processes. It regulates the cell cycle by inducing a transient G1 arrest, allowing time for DNA repair before replication, and controls the G2/M transition checkpoint to prevent the division of cells with damaged DNA (Aubrey2016Tumor-Suppressor). p53 also plays a role in apoptosis by activating genes involved in both intrinsic and extrinsic apoptotic pathways (Aubrey2016Tumor-Suppressor).

The p53 protein is primarily active in the nucleus, where it binds to specific DNA sequences to regulate gene expression. It forms a homotetramer that interacts with DNA, and its activity is modulated by post-translational modifications such as phosphorylation and acetylation (Aubrey2016Tumor-Suppressor; Hafner2019The). Through these mechanisms, p53 maintains cellular homeostasis and prevents tumorigenesis by ensuring the integrity of the genome (Levine2019The).

## Clinical Significance
Mutations in the TP53 gene are among the most common genetic alterations in human cancers, affecting over 50% of primary tumors. These mutations often result in the loss of tumor suppressive functions and can lead to a gain-of-function, contributing to cancer progression and chemoresistance (Chen2022Mutant; Hernández2021Tumor). TP53 mutations are predominantly missense mutations, particularly in the DNA-binding domain, and are associated with more aggressive cancer subtypes (Olivier2009TP53; Chen2022Mutant).

Li-Fraumeni syndrome (LFS) is a hereditary disorder caused by germline TP53 mutations, predisposing individuals to a variety of early-onset cancers, including breast cancer, sarcomas, brain tumors, and adrenocortical carcinomas (Robles2009Clinical; Malkin1990Germ). These mutations are often found in families with a history of multiple cancers, fitting a rare autosomal dominant gene model (Malkin1990Germ).

Environmental factors can induce specific TP53 mutations, such as aflatoxin exposure leading to hepatocellular carcinoma and UV radiation causing skin cancers (Robles2009Clinical). The presence of TP53 mutations is often associated with poor prognosis in various cancers, including breast, lung, and colorectal cancers (Chen2022Mutant; Donehower2019Integrated).

## Interactions
The TP53 protein, also known as p53, is a crucial tumor suppressor involved in various cellular processes through its interactions with other proteins and nucleic acids. One of the most significant interactions is with the murine double minute 2 (MDM2) protein, which regulates p53 by promoting its degradation. MDM2 binds to p53, inhibiting its function and leading to its ubiquitination and subsequent proteasomal degradation (Wang2012Targeting). This interaction is a target for cancer therapeutics, with efforts focused on developing small-molecule inhibitors to block MDM2 and reactivate p53 (Wang2012Targeting).

p53 also interacts with other proteins such as 53BP1, which enhances p53-mediated transcription activation and plays a role in the DNA damage response (Ma2005The). The interaction involves the BRCT domains of 53BP1 binding to specific regions of p53 (Ma2005The). Additionally, p53 interacts with replication protein A (RPA), which mediates suppression of homologous recombination (Ma2005The).

The TP53 gene is frequently mutated in cancers, affecting its interactions with proteins like MDM2 and EP300, which are involved in ubiquitination and transcriptional regulation, respectively (Engin2016StructureBased). These mutations can alter the binding affinities and functional outcomes of p53 interactions, impacting tumorigenesis and patient survival (Engin2016StructureBased).


## References


[1. (Olivier2009TP53) M. Olivier, M. Hollstein, and P. Hainaut. Tp53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harbor Perspectives in Biology, 2(1):a001008–a001008, November 2009. URL: http://dx.doi.org/10.1101/cshperspect.a001008, doi:10.1101/cshperspect.a001008. This article has 2352 citations and is from a peer-reviewed journal.](https://doi.org/10.1101/cshperspect.a001008)

[2. (Engin2016StructureBased) H. Billur Engin, Jason F. Kreisberg, and Hannah Carter. Structure-based analysis reveals cancer missense mutations target protein interaction interfaces. PLOS ONE, 11(4):e0152929, April 2016. URL: http://dx.doi.org/10.1371/journal.pone.0152929, doi:10.1371/journal.pone.0152929. This article has 82 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0152929)

[3. (Hernández2021Tumor) Liz J. Hernández Borrero and Wafik S. El-Deiry. Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1876(1):188556, August 2021. URL: http://dx.doi.org/10.1016/j.bbcan.2021.188556, doi:10.1016/j.bbcan.2021.188556. This article has 302 citations.](https://doi.org/10.1016/j.bbcan.2021.188556)

[4. (Chen2022Mutant) Xiaohua Chen, Taotao Zhang, Wei Su, Zhihui Dou, Dapeng Zhao, Xiaodong Jin, Huiwen Lei, Jing Wang, Xiaodong Xie, Bo Cheng, Qiang Li, Hong Zhang, and Cuixia Di. Mutant p53 in cancer: from molecular mechanism to therapeutic modulation. Cell Death &amp; Disease, November 2022. URL: http://dx.doi.org/10.1038/s41419-022-05408-1, doi:10.1038/s41419-022-05408-1. This article has 63 citations.](https://doi.org/10.1038/s41419-022-05408-1)

[5. (Römer2006p53—A) Lin Römer, Christian Klein, Alexander Dehner, Horst Kessler, and Johannes Buchner. P53—a natural cancer killer: structural insights and therapeutic concepts. Angewandte Chemie International Edition, 45(39):6440–6460, September 2006. URL: http://dx.doi.org/10.1002/anie.200600611, doi:10.1002/anie.200600611. This article has 85 citations.](https://doi.org/10.1002/anie.200600611)

[6. (Levine2019The) Arnold J Levine. The many faces of p53: something for everyone. Journal of Molecular Cell Biology, 11(7):524–530, July 2019. URL: http://dx.doi.org/10.1093/jmcb/mjz026, doi:10.1093/jmcb/mjz026. This article has 115 citations and is from a peer-reviewed journal.](https://doi.org/10.1093/jmcb/mjz026)

[7. (Robles2009Clinical) A. I. Robles and C. C. Harris. Clinical outcomes and correlates of tp53 mutations and cancer. Cold Spring Harbor Perspectives in Biology, 2(3):a001016–a001016, November 2009. URL: http://dx.doi.org/10.1101/cshperspect.a001016, doi:10.1101/cshperspect.a001016. This article has 208 citations and is from a peer-reviewed journal.](https://doi.org/10.1101/cshperspect.a001016)

[8. (Donehower2019Integrated) Lawrence A. Donehower, Thierry Soussi, Anil Korkut, Yuexin Liu, Andre Schultz, Maria Cardenas, Xubin Li, Ozgun Babur, Teng-Kuei Hsu, Olivier Lichtarge, John N. Weinstein, Rehan Akbani, and David A. Wheeler. Integrated analysis of tp53 gene and pathway alterations in the cancer genome atlas. Cell Reports, 28(5):1370-1384.e5, July 2019. URL: http://dx.doi.org/10.1016/j.celrep.2019.07.001, doi:10.1016/j.celrep.2019.07.001. This article has 383 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.celrep.2019.07.001)

[9. (Wang2012Targeting) Shaomeng Wang, Yujun Zhao, Denzil Bernard, Angelo Aguilar, and Sanjeev Kumar. Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics, pages 57–79. Springer Berlin Heidelberg, 2012. URL: http://dx.doi.org/10.1007/978-3-642-28965-1_2, doi:10.1007/978-3-642-28965-1_2. This article has 56 citations.](https://doi.org/10.1007/978-3-642-28965-1_2)

[10. (Uversky2016p53) Vladimir Uversky. P53 proteoforms and intrinsic disorder: an illustration of the protein structure–function continuum concept. International Journal of Molecular Sciences, 17(11):1874, November 2016. URL: http://dx.doi.org/10.3390/ijms17111874, doi:10.3390/ijms17111874. This article has 134 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms17111874)

[11. (Aubrey2016Tumor-Suppressor) Brandon J. Aubrey, Andreas Strasser, and Gemma L. Kelly. Tumor-suppressor functions of the tp53 pathway. Cold Spring Harbor Perspectives in Medicine, 6(5):a026062, May 2016. URL: http://dx.doi.org/10.1101/cshperspect.a026062, doi:10.1101/cshperspect.a026062. This article has 321 citations and is from a peer-reviewed journal.](https://doi.org/10.1101/cshperspect.a026062)

[12. (Malkin1990Germ) David Malkin, Frederick P. Li, Louise C. Strong, Joseph F. Fraumeni, Camille E. Nelson, David H. Kim, Jayne Kassel, Magdalena A. Gryka, Farideh Z. Bischoff, Michael A. Tainsky, and Stephen H. Friend. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science, 250(4985):1233–1238, November 1990. URL: http://dx.doi.org/10.1126/science.1978757, doi:10.1126/science.1978757. This article has 2641 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1126/science.1978757)

[13. (Joerger2010The) A. C. Joerger and A. R. Fersht. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harbor Perspectives in Biology, 2(6):a000919–a000919, February 2010. URL: http://dx.doi.org/10.1101/cshperspect.a000919, doi:10.1101/cshperspect.a000919. This article has 258 citations and is from a peer-reviewed journal.](https://doi.org/10.1101/cshperspect.a000919)

[14. (Hafner2019The) Antonina Hafner, Martha L. Bulyk, Ashwini Jambhekar, and Galit Lahav. The multiple mechanisms that regulate p53 activity and cell fate. Nature Reviews Molecular Cell Biology, 20(4):199–210, March 2019. URL: http://dx.doi.org/10.1038/s41580-019-0110-x, doi:10.1038/s41580-019-0110-x. This article has 759 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41580-019-0110-x)

[15. (Ma2005The) Buyong Ma, Yongping Pan, K Gunasekaran, Ozlem Keskin, R Babu Venkataraghavan, Arnold J Levine, and Ruth Nussinov. The contribution of the trp/met/phe residues to physical interactions of p53 with cellular proteins. Physical Biology, 2(2):S56–S66, June 2005. URL: http://dx.doi.org/10.1088/1478-3975/2/2/S06, doi:10.1088/1478-3975/2/2/s06. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.1088/1478-3975/2/2/S06)